Matthew Ferry and Sarah Bloch authored an article for the Daily Journal discussing the top ten aspects alternative protein companies should consider when planning for and negotiating research and commercial agreements.
"Have a clear strategy to protect your background IP [intellectual property]," the authors wrote. "Every inventive step in the development and manufacturing process should be independently protected either as a trade secret or through patents, including any genetic constructs and cell lines, methods of scale-up and manufacture, and the final products. Trade secrets can be valuable but must be subject to reasonable secrecy efforts to be protected in court. Therefore, technologies that are reverse-engineerable from or detectable in products are typically better protected with patents."
Read the full article.
